Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals; Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones
Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals; Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones
Vertex will utilize Orna's novel and proprietary LNP delivery solutions to enhance efforts in developing next generation gene editing therapies for patients with Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT).
Vertex將利用Orna的新穎和專有的LNP遞送解決方案，增強開發下一代基因編輯療法的努力，以惠及鐮狀細胞病（SCD）和輸血依賴性β地中海貧血（TDT）患者。
Under the terms of the agreement, Orna will receive upfront payments of $65 million, including an investment in the form of a convertible note, and is eligible to receive up to $635 million based upon the achievement of specified pre-clinical, research, development, regulatory and commercial milestones related to SCD/TDT products.
根據協議條款，Orna將獲得6500萬美元的預付款，其中包括以可轉換票據形式的投資，並有資格根據與SCD/TDT產品相關的特定臨牀前、研究、開發、監管和商業里程碑的實現，獲得高達63500萬美元的款項。
Additionally, Orna is further eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional indications.
此外，如果Vertex在額外適應症中選擇權利，Orna還可根據每個產品獲得高達36500萬美元的額外期權費用和里程碑款項，最多可涵蓋十個額外產品。
